Onxeo (Euronext Paris: ONXEO), created by a merger between French company BioAlliance Pharma, and Danish biopharmaceutical company Topotarget, confirmed receipt of $25 million related to the approval of Beleodaq (belinostat) by the US Food and Drug Administration from its US partner Spectrum Pharmaceuticals (Nasdaq: SPPI).
Early July 2014, Beleodaq was granted conditional marketing authorization for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) under the FDA's accelerated approval program (The Pharma Letter July 4). Related to that, Onxeo US partner Spectrum Pharmaceuticals has paid the $25 million milestone as planned by contract.
Beleodaq already generating sales
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze